Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference
Neuronetics (NASDAQ: STIM) announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 6, 2024, at 10:00am Central Time. The presentation will be accessible via a live audio webcast on their investor relations webpage. Neuronetics, a medical technology company, focuses on developing and marketing products to improve the lives of patients with neurohealth disorders.
- Neuronetics is participating in a high-profile investor conference, potentially increasing visibility and investor interest.
- The live audio webcast provides transparency and accessibility for investors to gain insights directly from the management team.
- The PR lacks detailed financial or operational updates, which might be seen as a missed opportunity to provide more substantial insights.
- No new product developments or significant company milestones were announced, potentially leading to investor disappointment.
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When and where will Neuronetics present at the William Blair 44th Annual Growth Stock Conference?
How can I access the live webcast of Neuronetics' presentation?
What is the focus of Neuronetics as a company?
What is the stock symbol for Neuronetics?
